Risk and Prevention for Highly Penetrant Genes

go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.CrossRefPubMed Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://​doi.​org/​10.​3322/​caac.​21332.CrossRefPubMed

go back to reference Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143–53. https://doi.org/10.1056/NEJMra0802968.CrossRefPubMed Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143–53. https://​doi.​org/​10.​1056/​NEJMra0802968.CrossRefPubMed

go back to reference Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian Cancer study group. J Clin Oncol. 2012;30:2654–63. https://doi.org/10.1200/JCO.2011.39.8545.CrossRefPubMedPubMedCentral Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian Cancer study group. J Clin Oncol. 2012;30:2654–63. https://​doi.​org/​10.​1200/​JCO.​2011.​39.​8545.CrossRefPubMedPubMedCentral

go back to reference Couch, Fergus. SABCS 2016. Couch, Fergus. SABCS 2016.

go back to reference Peshkin BN, Isaacs C (2018). Prevalence of BRCA1 and BRCA2 mutations and associated cancer risks. In T. W. Post (Ed.), UpToDate. Retrieved from http://www.uptodate.com Peshkin BN, Isaacs C (2018). Prevalence of BRCA1 and BRCA2 mutations and associated cancer risks. In T. W. Post (Ed.), UpToDate. Retrieved from http://​www.​uptodate.​com

go back to reference Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16. https://doi.org/10.1001/jama.2017.7112.CrossRefPubMed Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16. https://​doi.​org/​10.​1001/​jama.​2017.​7112.CrossRefPubMed

go back to reference Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365–72.CrossRefPubMed Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365–72.CrossRefPubMed

go back to reference Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001;80(3):341–5.CrossRefPubMed Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001;80(3):341–5.CrossRefPubMed

go back to reference Curtis RE, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E, et al (editors). 2006, pages 189–214. Curtis RE, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E, et al (editors). 2006, pages 189–214.

go back to reference Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404–10. https://doi.org/10.1200/JCO.2009.24.2495.CrossRefPubMedPubMedCentral Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404–10. https://​doi.​org/​10.​1200/​JCO.​2009.​24.​2495.CrossRefPubMedPubMedCentral

go back to reference Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, CIMBA Consortium., Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg E, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, de Paepe A, Poppe B, Claes K, de Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomäki K, van der Hout A, Hogervorst FB, Verhoef S, Collée JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, Gómez Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Złowocka-Perłowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015;313(13):1347–1361. doi: https://doi.org/10.1001/jama.2014.5985. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, CIMBA Consortium., Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg E, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, de Paepe A, Poppe B, Claes K, de Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomäki K, van der Hout A, Hogervorst FB, Verhoef S, Collée JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, Gómez Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Złowocka-Perłowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015;313(13):1347–1361. doi: https://​doi.​org/​10.​1001/​jama.​2014.​5985.

go back to reference Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811–4.CrossRefPubMedPubMedCentral Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811–4.CrossRefPubMedPubMedCentral

go back to reference Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–6.CrossRef Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–6.CrossRef

go back to reference Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21(22):4222–7.CrossRefPubMed Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21(22):4222–7.CrossRefPubMed

go back to reference NCCN Practice Guidelines Hereditary Breast and/or Ovarian Cancer v.1.2018. NCCN Practice Guidelines Hereditary Breast and/or Ovarian Cancer v.1.2018.

go back to reference Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660. https://doi.org/10.1136/bmj.e5660.CrossRefPubMedPubMedCentral Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660. https://​doi.​org/​10.​1136/​bmj.​e5660.CrossRefPubMedPubMedCentral

go back to reference Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664–9. https://doi.org/10.1200/JCO.2009.27.0835.CrossRefPubMedPubMedCentral Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664–9. https://​doi.​org/​10.​1200/​JCO.​2009.​27.​0835.CrossRefPubMedPubMedCentral

go back to reference Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33(10):1128–35. https://doi.org/10.1200/JCO.2014.56.8626.CrossRefPubMedPubMedCentral Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33(10):1128–35. https://​doi.​org/​10.​1200/​JCO.​2014.​56.​8626.CrossRefPubMedPubMedCentral

go back to reference Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335–44.CrossRefPubMedPubMedCentral Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335–44.CrossRefPubMedPubMedCentral

go back to reference Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75. https://doi.org/10.1001/jama.2010.1237. CrossRefPubMedPubMedCentral Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75. https://​doi.​org/​10.​1001/​jama.​2010.​1237.​ CrossRefPubMedPubMedCentral

go back to reference Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL, et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660–9. https://doi.org/10.1016/j.amjsurg.2016.06.010.CrossRefPubMed Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL, et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660–9. https://​doi.​org/​10.​1016/​j.​amjsurg.​2016.​06.​010.CrossRefPubMed

go back to reference Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26(24):3943–9. https://doi.org/10.1200/JCO.2007.13.9568.CrossRefPubMed Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26(24):3943–9. https://​doi.​org/​10.​1200/​JCO.​2007.​13.​9568.CrossRefPubMed

go back to reference Jakub JW, Peled AW, Gray RJ, Greenup RA, Kiluk JV, Sacchini V, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg. 2018;153(2):123–9. https://doi.org/10.1001/jamasurg.2017.3422.CrossRefPubMed Jakub JW, Peled AW, Gray RJ, Greenup RA, Kiluk JV, Sacchini V, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg. 2018;153(2):123–9. https://​doi.​org/​10.​1001/​jamasurg.​2017.​3422.CrossRefPubMed

go back to reference Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491–6.CrossRefPubMed Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491–6.CrossRefPubMed

go back to reference Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(5) https://doi.org/10.1093/jnci/djv033. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(5) https://​doi.​org/​10.​1093/​jnci/​djv033.

go back to reference Chai X, Domchek S, Kauff N, Rebbeck T, Chen J. RE: breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(9) https://doi.org/10.1093/jnci/djv217. Chai X, Domchek S, Kauff N, Rebbeck T, Chen J. RE: breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(9) https://​doi.​org/​10.​1093/​jnci/​djv217.

go back to reference Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2016;109(1):djw177. https://doi.org/10.1093/jnci/djw177.CrossRefPubMed Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2016;109(1):djw177. https://​doi.​org/​10.​1093/​jnci/​djw177.CrossRefPubMed

go back to reference Domchek SM, Friebel T, Neuhausen SL, Lynch HT, Singer CF, Eeles RA, Isaacs C, Tung NM, Ganz PA, Couch FJ, Weitzel JN, Olopade OI, Rubinstein WS, Tomlinson GE, Pichert GC, Daly MB, Matloff ET, Evans DG, Garber JE, Rebbeck TR, PROSE Consortium Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 1501). 2011 ASCO Annual Meeting. Domchek SM, Friebel T, Neuhausen SL, Lynch HT, Singer CF, Eeles RA, Isaacs C, Tung NM, Ganz PA, Couch FJ, Weitzel JN, Olopade OI, Rubinstein WS, Tomlinson GE, Pichert GC, Daly MB, Matloff ET, Evans DG, Garber JE, Rebbeck TR, PROSE Consortium Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 1501). 2011 ASCO Annual Meeting.

go back to reference Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091–9. https://doi.org/10.1200/JCO.2012.47.8313.CrossRefPubMedPubMedCentral Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091–9. https://​doi.​org/​10.​1200/​JCO.​2012.​47.​8313.CrossRefPubMedPubMedCentral

go back to reference Peshkin BN, Isaacs C (2017). Overview of hereditary breast and ovarian cancer syndromes. In T. W. Post (Ed.), UpToDate. Retrieved from http://www.uptodate.com. Peshkin BN, Isaacs C (2017). Overview of hereditary breast and ovarian cancer syndromes. In T. W. Post (Ed.), UpToDate. Retrieved from http://​www.​uptodate.​com.

go back to reference Liu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119(19):3454–61. https://doi.org/10.1002/cncr.28183. CrossRef Liu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119(19):3454–61. https://​doi.​org/​10.​1002/​cncr.​28183.​ CrossRef

go back to reference Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53. https://doi.org/10.1200/JCO.2013.53.2820.CrossRefPubMedPubMedCentral Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53. https://​doi.​org/​10.​1200/​JCO.​2013.​53.​2820.CrossRefPubMedPubMedCentral

go back to reference Segev Y, Iqbal J, Lubinski, Gronwald J, Lynch HT, Moller PJ, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013;130(1):127–31. https://doi.org/10.1016/j.ygyno.2013.03.027. CrossRefPubMed Segev Y, Iqbal J, Lubinski, Gronwald J, Lynch HT, Moller PJ, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013;130(1):127–31. https://​doi.​org/​10.​1016/​j.​ygyno.​2013.​03.​027.​ CrossRefPubMed

go back to reference Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine Cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434–40. https://doi.org/10.1001/jamaoncol.2016.1820.CrossRefPubMedPubMedCentral Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine Cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434–40. https://​doi.​org/​10.​1001/​jamaoncol.​2016.​1820.CrossRefPubMedPubMedCentral

go back to reference Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–98. https://doi.org/10.1200/JCO.2013.48.9021.CrossRefPubMed Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–98. https://​doi.​org/​10.​1200/​JCO.​2013.​48.​9021.CrossRefPubMed

go back to reference Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275–84. https://doi.org/10.1016/j.ejca.2010.04.018.CrossRefPubMed Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275–84. https://​doi.​org/​10.​1016/​j.​ejca.​2010.​04.​018.CrossRefPubMed

go back to reference Schrijver LH, Olsson H, Antonis A, Milne R, Phillips K, Andrieu N, et al. Oral contraceptive use and breast cancer risk: a cohort study of BRCA1 and mutation carriers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017:77(13 Suppl):Abstract nr 4276, Abstract 4276: Oral contraceptive use and breast cancer risk: a cohort study ofBRCA1andBRCA2mutation carriers. Schrijver LH, Olsson H, Antonis A, Milne R, Phillips K, Andrieu N, et al. Oral contraceptive use and breast cancer risk: a cohort study of BRCA1 and mutation carriers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017:77(13 Suppl):Abstract nr 4276, Abstract 4276: Oral contraceptive use and breast cancer risk: a cohort study ofBRCA1andBRCA2mutation carriers.

go back to reference Micropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, et al. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer. 2018;118(2):266–76. https://doi.org/10.1038/bjc.2017.429.CrossRef Micropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, et al. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer. 2018;118(2):266–76. https://​doi.​org/​10.​1038/​bjc.​2017.​429.CrossRef

go back to reference Evans DG (2017). Li-fraumeni syndrome. In T. W. Post (Ed.), UpToDate. Retrieved from http://www.uptodate.com Evans DG (2017). Li-fraumeni syndrome. In T. W. Post (Ed.), UpToDate. Retrieved from http://​www.​uptodate.​com

go back to reference Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast Cancer. JAMA Oncol. 2017;3(9):1190–6. https://doi.org/10.1001/jamaoncol.2017.0424.CrossRefPubMedPubMedCentral Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast Cancer. JAMA Oncol. 2017;3(9):1190–6. https://​doi.​org/​10.​1001/​jamaoncol.​2017.​0424.CrossRefPubMedPubMedCentral

go back to reference Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643–50.PubMed Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643–50.PubMed

go back to reference Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010;47(11):771–4. https://doi.org/10.1136/jmg.2010.078113.CrossRefPubMed Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010;47(11):771–4. https://​doi.​org/​10.​1136/​jmg.​2010.​078113.CrossRefPubMed

go back to reference Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54(5):1298–304.PubMed Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54(5):1298–304.PubMed

go back to reference Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295–305. https://doi.org/10.1016/S1470-2045(16)30249-2.CrossRefPubMed Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295–305. https://​doi.​org/​10.​1016/​S1470-2045(16)30249-2.CrossRefPubMed

go back to reference Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. Baseline surveillance in li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol. 2017;3(12):1634–9. https://doi.org/10.1001/jamaoncol.2017.1968.CrossRefPubMedPubMedCentral Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. Baseline surveillance in li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol. 2017;3(12):1634–9. https://​doi.​org/​10.​1001/​jamaoncol.​2017.​1968.CrossRefPubMedPubMedCentral

go back to reference Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105(21):1607–16. https://doi.org/10.1093/jnci/djt277.CrossRefPubMed Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105(21):1607–16. https://​doi.​org/​10.​1093/​jnci/​djt277.CrossRefPubMed

go back to reference Ngeow J, Sesock K, Eng C. Breast Cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat. 2017;165(1):1–8. https://doi.org/10.1007/s10549-015-3665-z.CrossRefPubMed Ngeow J, Sesock K, Eng C. Breast Cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat. 2017;165(1):1–8. https://​doi.​org/​10.​1007/​s10549-015-3665-z.CrossRefPubMed

go back to reference Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol. 2014;32(17):1818–24. https://doi.org/10.1200/JCO.2013.53.6656.CrossRefPubMedPubMedCentral Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol. 2014;32(17):1818–24. https://​doi.​org/​10.​1200/​JCO.​2013.​53.​6656.CrossRefPubMedPubMedCentral

go back to reference Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7. https://doi.org/10.1158/1078-0432.CCR-11-2283.CrossRefPubMedPubMedCentral Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7. https://​doi.​org/​10.​1158/​1078-0432.​CCR-11-2283.CrossRefPubMedPubMedCentral

go back to reference Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50(4):255–63. https://doi.org/10.1136/jmedgenet-2012-101339.CrossRefPubMed Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50(4):255–63. https://​doi.​org/​10.​1136/​jmedgenet-2012-101339.CrossRefPubMed

go back to reference Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Yntema HG, Evans DG, Colas C. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Familial Cancer. 2014;13(1):57–63. https://doi.org/10.1007/s10689-013-9674-3.CrossRefPubMed Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Yntema HG, Evans DG, Colas C. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Familial Cancer. 2014;13(1):57–63. https://​doi.​org/​10.​1007/​s10689-013-9674-3.CrossRefPubMed

go back to reference Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.CrossRefPubMed Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.CrossRefPubMed

go back to reference NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colorectal Cancer Screening Version 2.2017. NCCN.org. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colorectal Cancer Screening Version 2.2017. NCCN.​org.

go back to reference Pharoah PD, Guilford P, Caldas C. International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.CrossRefPubMed Pharoah PD, Guilford P, Caldas C. International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.CrossRefPubMed

go back to reference NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Gastric Cancer Version 5.2017. NCCN.org. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Gastric Cancer Version 5.2017. NCCN.​org.

go back to reference Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. https://doi.org/10.1056/NEJMoa1400382.a.CrossRefPubMedPubMedCentral Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. https://​doi.​org/​10.​1056/​NEJMoa1400382.​a.CrossRefPubMedPubMedCentral